Navigation Links
Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provid's Unique MS Drug Candidate
Date:11/17/2010

NEW YORK and NORTH BRUNSWICK, N.J., Nov. 17, 2010 /PRNewswire/ -- Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced an expansion of their partnership to support Provid's preclinical studies of their candidate MS drug, PV-267.  This novel, highly selective small molecule is designed to block a critical step in the autoimmune process of MS, which leads to the destruction of the body's protective myelin in the central nervous system and to the ultimate accumulation of disability.  

The expanded partnership will enable Provid to enhance knowledge of the immune mechanisms involved in the activity of PV-267, paving the way for future development and clinical studies.  The biological studies will be carried out by Dr. Thomas Forsthuber, Provid's collaborator and a leading immunologist at the University of Texas San Antonio.  

"The partnership between Fast Forward and Provid was begun in May 2009 and helped fund important research," noted Dr. Gary Olson, Provid's President and CEO.  "In these studies, PV-267 was shown to be active in an animal model of MS in transgenic mice that carry the human gene for HLA-DR2, a disease-associated molecule that is involved in the attack of the immune system on myelin, the insulating protein on nerves that are damaged in MS."  Dr. Olson added, "DR2 is present in about 60% of the MS population and PV-267 was designed to be a potent and selective blocker of DR2.  This specificity suggests that PV-267 could have a better safety profile compared with immune-modifying therapies since it will not affect other, normal immune responses."  

The partnership with Provid is one of a series of partnerships between Fast Forward and early stage biotechnology companies. "The results of our
'/>"/>

SOURCE Provid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
8. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
(Date:9/22/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... that TUV-SUD and The Medicinal Evaluation Board of ... granted its request for a label expansion for ... approved in July 2013 for use in the ...
(Date:9/22/2014)... , Sept. 22, 2014  Seres Health, a ... to the human microbiome, today announced that it has ... 2014,s Fierce 15 biotechnology companies, designating it as one ... industry.  "Amid a great deal of ... its focus and commitment to practical therapeutic development," says ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Seres Health Named a "Fierce 15" Biotech Company for 2014 2
(Date:9/22/2014)... Norton HealthDay Reporter MONDAY, ... better when newborn intensive care units (NICU) set up private ... new study finds. Researchers at one children,s hospital found ... less distressed when their NICU switched from the traditional "open-bay" ... online Sept. 22 in the journal Pediatrics , add ...
(Date:9/22/2014)... Malaysia today became a founding partner in the Global ... to promoting young talent in science, technology, engineering and ... New York Academy of Sciences (NYAS), Malaysian Prime Minister ... Monday Sept. 22. , With the goal of developing ... countries by 2020, the initiative will create a host ...
(Date:9/22/2014)... two-generation approaches to reducing poverty that help children ... researchers, advocates, and foundations. By combining education and ... to jobs that offer a path out of ... children, these programs aim to improve the life ... new report from the National Center for Children ...
(Date:9/22/2014)... York, New York (PRWEB) September 22, 2014 ... associated with the use of power morcellators ( ... LLP notes a new report detailing the continued ... warnings from federal regulators that specifically discouraged these ... physicians believe that the potential cancer risks associated ...
(Date:9/22/2014)... Pain does not need to rule your life anymore! ... book designed to guide the individual who suffers with chronic ... is written to help the reader who is struggling with ... a pain-free life — a daily “go-to” guide on breaking ... has become an epidemic, with over 100 million Americans suffering ...
Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2
... significantly reduce demand? A new study suggests it will. ... of one side of a cigarette pack with a text ... labels, which include graphic images of lung and mouth cancer, ... 404 adult smokers from four states participated in an experimental ...
... Gordon HealthDay Reporter , MONDAY, Aug. 8 (HealthDay ... at home may reach unsafe temperatures by the time a ... in an insulated container with ice packs. A new ... of the food sent from home was at an unsafe ...
... Aug. 8 (HealthDay News) -- Youth sports programs need ... illness, says an updated policy statement from the American ... can safely participate in outdoor sports and activities in ... adults sometimes create situations that are potentially dangerous," Dr. ...
... prostate cancer expect better recovery from the side effects of ... operation, a University of Michigan Comprehensive Cancer Center study finds. ... of men had expected to have better urinary continence and ... before it the exact opposite of what typically happens. ...
... may not be enough to treat symptoms in neonates ... study from Nationwide Children,s Hospital, this is the first ... neonates based on how and what is refluxed. ... in infants at risk of the life-threatening events chronic ...
... the latest issue of Nature , researchers at ... Pennsylvania clarify the role of two proteins key to ... Notch passes off much of its role during T-cell ... required for many aspects of immunity, and understanding how ...
Cached Medicine News:Health News:Study: Graphic warning labels reduce demand for cigarettes 2Health News:Are Kids Brown-Bagging Bacteria? 2Health News:Are Kids Brown-Bagging Bacteria? 3Health News:Kids Can Safely Play Sports in Hot Weather: Experts 2Health News:Men have overly optimistic expectations about recovery from prostate cancer surgery, U-M study finds 2Health News:New study helps clarify symptoms and characteristics of acid reflux in neonates 2Health News:Penn researchers describe key molecule that keeps immune cell development on track 2
... Jenner Stain is used for staining ... one of the oldest stain formulations ... results similar to that of Giemsa ... appear brighter red; basophilic granules and ...
... Our Buffered Wright-Giemsa Stain ... that contains the fixative, buffer, ... convenient staining of blood smears. ... 32-oz. bottle for ease of ...
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
Medicine Products: